TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
A view showing the close relationship between the mitral and aortic valves and how the overhang of a longer TAVR valve can interfere with the left ventricular outflow tract (LVOT). Image from a mitral echo assessment using Siemens eSie Valves software at ACC22.

The latest data on mitral valve infective endocarditis after TAVR

Self-expanding heart valves and the presence of significant PVL were both linked to a heightened risk of mitral valve infective endocarditis after TAVR. 

The American College of Cardiology (ACC) annual meeting is the premier source for the latest cardiac science. #ACC22

Links to the ACC.22 late-breaking clinical trials

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C. 

VIDEO: TAVR durability outperforms surgical valves

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

How the continued rise of TAVR has impacted SAVR outcomes

Did SAVR outcomes suffer due to the rapid rise of TAVR? A team of researchers aimed to find out with a brand new analysis. 

The mitral valve visualized by a a GE NuVision 4D intra-cardiac echo (ICE) catheter a life-like surgical rendering technology on the Vivid E95 cardiac ultrasound system. The catheter was co-developed with Biosense Webster to perform EP procedures. It also can be used in place of TEE in structural heart procedures to eliminate the need for an interventional echocardiography.  #ACC22

Photo Gallery: ACC 2022 in pictures

Click through a wide variety of snapshots from ACC.22 in Washington, D.C. 

TAVR vs. surgery, FFR-guided PCI and DCB safety: Day 3 at ACC.22

Read our in-person coverage of the final day of ACC.22.

Same-day discharge after TAVR is feasible and safe, new Cleveland Clinic study confirms

Cleveland Clinic turned to same-day discharge after TAVR during the COVID-19 pandemic, finding considerable success. 

Q&A U.S. and European Valvular Heart Disease Guidelines: Lessons from Across the Pond

Sponsored by Medtronic

“Good harmony” is the way John P. Erwin III, MD, describes the synergy of the 2021 ESC/EACTS Guidelines for the management of valvular heart disease (VHD) released in August along with the ACC/AHA guidelines that rolled in December 2020.

Displaying 281 - 288 of 417

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup